GREY:ATBPF - Post by User
Post by
WalkOverTheStrton Mar 01, 2021 4:48pm
387 Views
Post# 32688154
Corp Update PH3
Corp Update PH3 from slide 16, nice to see some update info on trial
Multi-arm, placebo-controlled trial in the United States
- 12-week treatment duration in approximately 600 patients with OA of the knee
- Two treatment arms to establish lowest effective dose
• Primary endpoint: change in pain as measured by WOMAC
- Secondary endpoints: WOMAC scores of Stiffness and Difficulty in Performing Daily Activities
• Adaptive design - Independent Data Monitoring Committee (IDMC) to evaluate data once 50% of patients have completed treatment — allows for increase in sample size to preserve statistical power
• Initiation expected in H2 2021 — fully funded
https://antibethera.com/wp-content/uploads/2021/02/Antibe-Corporate-Presentation-February-2021.pdf